Governance

Previously a Lecturer at Glasgow Caledonian University, David has numerous publications in physiology and pharmacology to his name and is a respected opinion leader in the use of human tissue for drug discovery. He chairs the Scottish Lifesciences Association’s special interest group in precision medicine, is a member of the NC3Rs/MHRA working party on human tissues in safety pharmacology and is an advocate for the wider global use of human cells and tissues in drug development.

Ms McNeil gained a M.Sc. in Stratified Medicine and Pharmacological Innovation at the University of Glasgow. Prior to that she developed her extensive business experience from various management level roles within the pharmaceutical industry where she worked for over 10 years, working mostly in the Oncology Divisions of AstraZeneca and Eli Lilly.

She held a British Heart Foundation Chair of Cardiovascular Medicine at the University of Glasgow between 1997 and 2010, as well as the directorship of the Cardiovascular Research Centre between 2000 and 2010. Her major research interests are in hypertension, cardiovascular genomics and systems medicine and her total research income in the last three years totals more than £30 million.

Carol has managerial responsibility for all operational functions of the College, including line management responsibility for all of the administrative and support staff in the College (>300). In addition to this role, Carol has responsibility for clinical research governance in partnership with NHS Greater Glasgow & Clyde, including compliance with legislation relating to the conduct of clinical trials.

Since 2000, he has managed ChimaeraBio, a specialist life sciences investment fund which he founded with Karen Reid and has been involved with a number of Scotland’s more successful life science companies including Haptogen (acquired by Wyeth), Qnostics (acquired by BBI plc) and D3 Technologies (acquired by Renishaw plc). Jim was also Chairman at Lumora on its very successful exit in 2015. He continues to be a Board Director of a number of Life Science companies, the Scottish Life Science Association and the Mercia Fund Investment Board.

From 2011 to 2013 he took up a part time secondment to Scottish Government as Healthcare Science Officer, and in 2014 joined NHS NSS as Director of Healthcare Science.

Current studies involve using the electronic medical register to link patient outcome to genomic information, including GWAS and next generation sequencing data. This will provide new drug targets for the prevention and treatment of such diseases and will also allow for more informed and personalised usage of current therapies.

Prior to founding Aridhia, David was the Co-Founder, Chairman and CEO of Atlantech Technologies, a communications software company that was sold to Cisco Systems in March 2000.David is the Founder and Trustee of the Kate MacAskill Foundation, a charitable organisation providing education, care and micro-enterprise funding for children and young adults in the developing world. He is also the Founder and Chairman of the Johari Foundation and is a Vice-President of UNICEF UK, the United Nations children’s fund.David holds honorary doctorates from Glasgow Caledonian University, the University of Paisley and the University of Strathclyde for services to Scottish science and philanthropy. He is a Fellow of the Royal Society of Edinburgh, Scotland’s National Academy of Science and Letters. In the 2010 New Year Honours List, David was awarded an OBE for charitable services in Scotland and overseas.

A respiratory physician who trained mainly in London (St Bartholomew's Hospital Medical College, Hammersmith Hospital, Royal Postgraduate Medical School and Imperial Cancer Research Fund), after MRC and then Wellcome Clinical Fellowships, Moira was appointed Professor of Respiratory Medicine and subsequently Sir George Franklin Professor of Medicine at the University of Sheffield. She moved to Edinburgh in 2014.Her research interests have focused on molecular mechanisms underlying acute inflammation in the context both of chronic inflammatory lung diseases such as COPD and of host defence against bacterial infection.